- Home
- VHC vs ACRV Comparison
VHC vs ACRV Comparison
Compare VHC & ACRV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- VHC
- ACRV
- Stock Information
- Founded
- VHC 2005
- ACRV 2018
- Country
- VHC United States
- ACRV United States
- Employees
- VHC N/A
- ACRV N/A
- Industry
- VHC Multi-Sector Companies
- ACRV Medicinal Chemicals and Botanical Products
- Sector
- VHC Miscellaneous
- ACRV Health Care
- Exchange
- VHC Nasdaq
- ACRV Nasdaq
- Market Cap
- VHC 35.7M
- ACRV 34.5M
- IPO Year
- VHC 1999
- ACRV 2022
- Fundamental
- Price
- VHC $7.55
- ACRV $1.21
- Analyst Decision
- VHC
- ACRV Buy
- Analyst Count
- VHC 0
- ACRV 7
- Target Price
- VHC N/A
- ACRV $17.60
- AVG Volume (30 Days)
- VHC 20.3K
- ACRV 527.1K
- Earning Date
- VHC 08-13-2025
- ACRV 08-12-2025
- Dividend Yield
- VHC N/A
- ACRV N/A
- EPS Growth
- VHC N/A
- ACRV N/A
- EPS
- VHC N/A
- ACRV N/A
- Revenue
- VHC $3,000.00
- ACRV N/A
- Revenue This Year
- VHC N/A
- ACRV N/A
- Revenue Next Year
- VHC N/A
- ACRV N/A
- P/E Ratio
- VHC N/A
- ACRV N/A
- Revenue Growth
- VHC N/A
- ACRV N/A
- 52 Week Low
- VHC $3.68
- ACRV $1.05
- 52 Week High
- VHC $13.89
- ACRV $10.16
- Technical
- Relative Strength Index (RSI)
- VHC 41.62
- ACRV 45.62
- Support Level
- VHC $7.60
- ACRV $1.16
- Resistance Level
- VHC $9.05
- ACRV $1.30
- Average True Range (ATR)
- VHC 1.24
- ACRV 0.09
- MACD
- VHC -0.16
- ACRV 0.03
- Stochastic Oscillator
- VHC 12.94
- ACRV 54.17
About VHC VirnetX Holding Corp
VirnetX Holding Corp is engaged in the business of commercializing a portfolio of patents. It is an Internet security software and technology company with patented technology for secure communications. The company's software and technology solutions, including its Secure Domain Name Registry and Technology, VirnetX One, War Room, VirnetX Matrix, and GABRIEL Connection Technology, are designed to be device and location-independent, and enable a secure real-time communication environment for all types of enterprise applications, services and critical infrastructures.
About ACRV Acrivon Therapeutics Inc.
Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.